HHGA
IMVT icon

Halbert Hargrove Global Advisors’s Immunovant IMVT Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-83
Closed -$1.34K – 557
2025
Q3 		$1.34K Buy
+83
New +$1.34K ﹤0.01% 634

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Halbert Hargrove Global Advisors's IMVT Position: Q4 2025 in Review

Halbert Hargrove Global Advisors sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 83 shares — an estimated $1.34K sold.

Halbert Hargrove Global Advisors first reported a position in IMVT in Q3 2025 and held it in 1 quarter. The position peaked at $1.34K in Q3 2025. 197 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Halbert Hargrove Global Advisors reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 83 Immunovant shares in Q4 2025, an estimated $1.34K.
  • Halbert Hargrove Global Advisors first reported a position in Immunovant in Q3 2025 and held it in 1 quarter.
  • Halbert Hargrove Global Advisors's Immunovant position peaked at $1.34K in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Halbert Hargrove Global Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.